James Bullard said he dissented on this week's Fed decision to lower rates by a quarter percentage point because he didn't think the cut was big enough.The Fedread more
More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
"I feel like I've contributed all I can to this primary election," he told MSNBC's "Morning Joe." "And it's clearly not my time. So I'm going to end my presidential campaign."2020 Electionsread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
The complaint made by an unnamed intelligence official about the president centers on Ukraine, the Washington post reported.Politicsread more
The Pentagon on Thursday said the recent attack on Saudi Arabian oil facilities were "sophisticated" and represented a "dramatic escalation" in tensions within the region.Defenseread more
U.S. stock futures are modestly higher, with the S&P 500 just a little more than 20 points away from July's all-time high ahead of Friday's open on Wall Street.Marketsread more
Bank of America says Amazon's plans to build its own fleet of carbon-neutral delivery trucks bode well for its bottom line.Investingread more
The show comes as social media platforms and legacy media companies alike have launched a flurry of original content alongside new streaming platforms like Apple TV+ and...Technologyread more
Pivotal Research Group began coverage of Roku with a sell rating on FridayInvestingread more
Two sites were hit on Saturday — the Abqaiq and Khurais oil facilities — which took out 5.7 million barrels per day of crude oil production.World Politicsread more
Alkermes stock surged more than 27 percent Friday after its depression drug met its main goal in a final-stage study.
ALKS 5461 proved effective in re-balancing brain function in patients with major depressive disorder that failed to benefit from other treatments, the company reported late Thursday. Alkermes will now meet with the Food and Drug Administration to determine the next steps toward regulatory approval.
According to the National Institute of Mental Health, depression is one of the most common mental disorders in the U.S., with an estimated 16 million adults reporting at least one major depressive episode in the past year.
The news followed earlier setbacks with drug. In January, Alkermes shares plummeted after ALKS 5461 failed to meet goals in an earlier Phase III trial.
Even with Friday's big gains, the company's shares remain far below the stock's 52-week high of $80.71. Alkermes shares ended the day at $55.62, gaining $12.11 during the session.